Influvac Tetra

B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It induces active immunity to prevent influenza infection caused by the included virus strains in adults and children.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Influvac Tetra is a quadrivalent influenza vaccine used for active immunization against seasonal flu viruses. - Seasonal influenza (A/H1N1): reduces incidence of infection caused by the H1N1 strain. - Seasonal influenza (A/H3N2): reduces incidence of infection caused by the H3N2 strain. - Seasonal influenza (B lineages): provides protection against both B/Victoria and B/Yamagata lineages included in the vaccine.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: localized erythema or edema around the injection area. - Low‑grade fever: transient temperature rise within 24 hours. - Headache: mild headache occurring shortly after vaccination. - Myalgia: muscle aches that resolve within a few days.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder that may develop weeks after vaccination. - High fever: persistent temperature above 39 °C. - Seizures: uncommon febrile seizures, especially in young children. - Severe allergic reaction: angioedema or bronchospasm.

Before administering Influvac Tetra, consider the following precautions: - Allergy assessment: avoid if known hypersensitivity to any vaccine component. - Acute illness: postpone vaccination in the presence of moderate or severe fever or infection. - Age restrictions: follow approved age indications for each formulation. - Pregnancy and lactation: consult a healthcare professional to weigh benefits against potential risks. - Immunocompromised patients: vaccine may elicit a reduced immune response; monitor effectiveness. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tetra may interact with other agents as follows: Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration within 4 weeks to prevent interference. - Immunoglobulin therapy: may diminish vaccine‑induced antibody response. Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): prophylactic use may blunt antibody production. - Immunosuppressive drugs: monitor for adequate serologic response. - Antiviral agents (e.g., oseltamivir) initiated before vaccination: may affect immunogenicity.